Gilead gives up sofosbuvir patent protection in China

14 August 2018
2019_biotech_test_vial_discovery_big

The USA-based non-profit campaigner on patents, I-MAK, has claimed a significant victory in its bid to bring hepatitis C treatments that were previously protected by patents to the world’s largest patient population.

I-MAK, which stands for Initiative for Medicines, Access & Knowledge, brought the patent challenge relating to sofosbuvir before China’s State Intellectual Property Office (SIPO).

"A growing list of countries have found Gilead’s patents on sofosbuvir wanting and insufficient"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology